Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer

BMC Cancer

Diane R Bielenberg³  Bruce R Zetter³  Arianne M Wilson¹  Derek T Phan¹  Matthew Migliozzi¹  Ivy Chung²  Jacqueline Banyard³ 

[1]Vascular Biology Program, Boston Children’s Hospital, Karp Family Research Laboratories, 300 Longwood Avenue, 02115 Boston, MA, USA

[2]Current address

[3] Department of Pharmacology, Faculty of Medicine, UM Cancer Research Institute, University of Malaya, 50603 Kuala Lumpur, Malaysia

[4]Department of Surgery, Harvard Medical School, 02115 Boston, MA, USA

关键词: New model;    uPA;    Beta4;    Integrin;    EpCAM;    Lymph node;    Lymphangiogenesis;    Angiogenesis;    Metastasis;    Migration;    Invasion;    Prostate cancer;   

Others  :  858762
DOI  :  10.1186/1471-2407-14-387

 received in 2013-09-18, accepted in 2014-05-22,  发布年份 2014

【 摘 要 】

Background

Understanding the complex, multistep process of metastasis remains a major challenge in cancer research. Metastasis models can reveal insights in tumor development and progression and provide tools to test new intervention strategies.

Methods

To develop a new cancer metastasis model, we used DU145 human prostate cancer cells and performed repeated rounds of orthotopic prostate injection and selection of subsequent lymph node metastases. Tumor growth, metastasis, cell migration and invasion were analyzed. Microarray analysis was used to identify cell migration- and cancer-related genes correlating with metastasis. Selected genes were silenced using siRNA, and their roles in cell migration and invasion were determined in transwell migration and Matrigel invasion assays.

Results

Our in vivo cycling strategy created cell lines with dramatically increased tumorigenesis and increased ability to colonize lymph nodes (DU145LN1-LN4). Prostate tumor xenografts displayed increased vascularization, enlarged podoplanin-positive lymphatic vessels and invasive margins. Microarray analysis revealed gene expression profiles that correlated with metastatic potential. Using gene network analysis we selected 3 significantly upregulated cell movement and cancer related genes for further analysis: EPCAM (epithelial cell adhesion molecule), ITGB4 (integrin β4) and PLAU (urokinase-type plasminogen activator (uPA)). These genes all showed increased protein expression in the more metastatic DU145-LN4 cells compared to the parental DU145. SiRNA knockdown of EpCAM, integrin-β4 or uPA all significantly reduced cell migration in DU145-LN4 cells. In contrast, only uPA siRNA inhibited cell invasion into Matrigel. This role of uPA in cell invasion was confirmed using the uPA inhibitors, amiloride and UK122.

Conclusions

Our approach has identified genes required for the migration and invasion of metastatic tumor cells, and we propose that our new in vivo model system will be a powerful tool to interrogate the metastatic cascade in prostate cancer.

【 授权许可】

   
2014 Banyard et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]American Cancer Society: Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012.
• [2]Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012, 62(4):220-241.
• [3]Smith JA Jr, Seaman JP, Gleidman JB, Middleton RG: Pelvic lymph node metastasis from prostatic cancer: influence of tumor grade and stage in 452 consecutive patients. J Urol 1983, 130(2):290-292.
• [4]Dadras SS, Paul T, Bertoncini J, Brown LF, Muzikansky A, Jackson DG, Ellwanger U, Garbe C, Mihm MC, Detmar M: Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003, 162(6):1951-1960.
• [5]Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, Koch MO: Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. J Urol 2005, 174(6):2181-2185.
• [6]Rinderknecht M, Detmar M: Tumor lymphangiogenesis and melanoma metastasis. J Cell Physiol 2008, 216(2):347-354.
• [7]Karakiewicz PI, Hutterer GC: Predictive models and prostate cancer. Nat Clin Pract Urol 2008, 5(2):82-92.
• [8]Sleeman JP, Thiele W: Tumor metastasis and the lymphatic vasculature. Int J Cancer 2009, 125(12):2747-2756.
• [9]Zwaans BM, Bielenberg DR: Potential therapeutic strategies for lymphatic metastasis. Microvasc Res 2007, 74(2–3):145-158.
• [10]Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T, Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group: Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012, 367(3):203-213.
• [11]Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA: Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol 2012, 30(25):3071-3076.
• [12]Stephenson RA, Dinney CP, Gohji K, Ordonez NG, Killion JJ, Fidler IJ: Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst 1992, 84(12):951-957.
• [13]Perrotte PJR, Bielenberg DR, Eve BY, Dinney CPN: Organ-specific angiogenesis and metastasis of human bladder carcinoma growing in athymic mice. Mol Urol 1997, 1(4):299-307.
• [14]Bielenberg DR, Fidler IJ: Regulation of Angiogenesis by the Organ Microenvironment. In Antiangiogenic Agents in Cancer Therapy. 6th edition. Edited by Teicher BA. Totowa: Humana Press; 1999:77-91.
• [15]Fidler IJ: The organ microenvironment and cancer metastasis. Differentiation 2002, 70(9–10):498-505.
• [16]Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
• [17]Sottnik JL, Zhang J, Macoska JA, Keller ET: The PCa tumor microenvironment. Cancer Microenviron 2011, 4(3):283-297.
• [18]Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ: Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 1996, 2(9):1627-1636.
• [19]Sobel RE, Sadar MD: Cell lines used in prostate cancer research: a compendium of old and new lines–part 1. J Urol 2005, 173(2):342-359.
• [20]Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF: Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978, 21(3):274-281.
• [21]Banyard J, Chung I, Wilson AM, Vetter G, Le Béchec A, Bielenberg DR, Zetter BR: Regulation of epithelial plasticity by miR-424 and miR-200 in a new prostate cancer metastasis model. Sci Rep 2013, 3:3151.
• [22]Chunthapong J, Seftor EA, Khalkhali-Ellis Z, Seftor RE, Amir S, Lubaroff DM, Heidger PM Jr, Hendrix MJ: Dual roles of E-cadherin in prostate cancer invasion. J Cell Biochem 2004, 91(4):649-661.
• [23]Yilmaz M, Christofori G: Mechanisms of motility in metastasizing cells. Mol Cancer Res 2010, 8(5):629-642.
• [24]Wong SY, Hynes RO: Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide? Cell Cycle 2006, 5(8):812-817.
• [25]Christiansen A, Detmar M: Lymphangiogenesis and cancer. Genes Cancer 2011, 2(12):1146-1158.
• [26]Datta K, Muders M, Zhang H, Tindall DJ: Mechanism of lymph node metastasis in prostate cancer. Future Oncol 2010, 6(5):823-836.
• [27]Yee DS, Shariat SF, Lowrance WT, Maschino AC, Savage CJ, Cronin AM, Scardino PT, Eastham JA: Prognostic significance of lymphovascular invasion in radical prostatectomy specimens. BJU Int 2010, 108(4):502-507.
• [28]Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993, 143(2):401-409.
• [29]Mumprecht V, Detmar M: Lymphangiogenesis and cancer metastasis. J Cell Mol Med 2009, 13(8A):1405-1416.
• [30]Diamond E, Lee GY, Akhtar NH, Kirby BJ, Giannakakou P, Tagawa ST, Nanus DM: Isolation and characterization of circulating tumor cells in prostate cancer. Front Oncol 2012, 2:131.
• [31]Ni J, Cozzi PJ, Duan W, Shigdar S, Graham PH, John KH, Li Y: Role of the EpCAM (CD326) in prostate cancer metastasis and progression. Cancer Metastasis Rev 2012, 31(3–4):779-791.
• [32]Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA: Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006, 94(1):128-135.
• [33]Poczatek RB, Myers RB, Manne U, Oelschlager DK, Weiss HL, Bostwick DG, Grizzle WE: Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol 1999, 162(4):1462-1466.
• [34]Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, Mihatsch MJ, Gasser TC, Bubendorf L: Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005, 113(4):619-628.
• [35]Benko G, Spajic B, Kruslin B, Tomas D: Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer. Urol Oncol 2013, 31(4):468-474.
• [36]Denzel S, Maetzel D, Mack B, Eggert C, Barr G, Gires O: Initial activation of EpCAM cleavage via cell-to-cell contact. BMC Cancer 2009, 9:402. BioMed Central Full Text
• [37]Thuma F, Zoller M: EpCAM-associated claudin-7 supports lymphatic spread and drug resistance in rat pancreatic cancer. Int J Cancer 2013, 133(4):855-866.
• [38]Nubel T, Preobraschenski J, Tuncay H, Weiss T, Kuhn S, Ladwein M, Langbein L, Zoller M: Claudin-7 regulates EpCAM-mediated functions in tumor progression. Mol Cancer Res 2009, 7(3):285-299.
• [39]Mercurio AM, Rabinovitz I, Shaw LM: The alpha 6 beta 4 integrin and epithelial cell migration. Curr Opin Cell Biol 2001, 13(5):541-545.
• [40]Giancotti FG: Targeting integrin beta4 for cancer and anti-angiogenic therapy. Trends Pharmacol Sci 2007, 28(10):506-511.
• [41]Yoshioka T, Otero J, Chen Y, Kim YM, Koutcher JA, Satagopan J, Reuter V, Carver B, de Stanchina E, Enomoto K, Greenberg NM, Scardino PT, Scher HI, Sawyers CL, Giancotti FG: Beta4 Integrin signaling induces expansion of prostate tumor progenitors. J Clin Invest 2013, 123(2):682-699.
• [42]Gerson KD, Maddula VS, Seligmann BE, Shearstone JR, Khan A, Mercurio AM: Effects of beta4 integrin expression on microRNA patterns in breast cancer. Biol Open 2012, 1(7):658-666.
• [43]Andreasen PA, Kjoller L, Christensen L, Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997, 72(1):1-22.
• [44]Hienert G, Kirchheimer JC, Pfluger H, Binder BR: Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. J Urol 1988, 140(6):1466-1469.
• [45]Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, Slawin KM: Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007, 25(4):349-355.
• [46]Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S: Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 1999, 39(2):123-129.
• [47]Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, Rao JS: RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 2005, 280(43):36529-36540.
• [48]Conn EM, Botkjaer KA, Kupriyanova TA, Andreasen PA, Deryugina EI, Quigley JP: Comparative analysis of metastasis variants derived from human prostate carcinoma cells: roles in intravasation of VEGF-mediated angiogenesis and uPA-mediated invasion. Am J Pathol 2009, 175(4):1638-1652.
• [49]Mamoune A, Kassis J, Kharait S, Kloeker S, Manos E, Jones DA, Wells A: DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling. Exp Cell Res 2004, 299(1):91-100.
• [50]O’Halloran TV, Ahn R, Hankins P, Swindell E, Mazar AP: The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target. Theranostics 2013, 3(7):496-506.
• [51]Sanchez-Tillo E, de Barrios O, Siles L, Amendola PG, Darling DS, Cuatrecasas M, Castells A, Postigo A: ZEB1 Promotes invasiveness of colorectal carcinoma cells through the opposing regulation of uPA and PAI-1. Clin Cancer Res 2013, 19(5):1071-1082.
• [52]Drake JM, Barnes JM, Madsen JM, Domann FE, Stipp CS, Henry MD: ZEB1 coordinately regulates laminin-332 and {beta}4 integrin expression altering the invasive phenotype of prostate cancer cells. J Biol Chem 2010, 285(44):33940-33948.
• [53]Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA, Drabkin HA: ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett 2010, 300(1):66-78.
• [54]Park SM, Gaur AB, Lengyel E, Peter ME: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008, 22(7):894-907.
• [55]Korpal M, Lee ES, Hu G, Kang Y: The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008, 283(22):14910-14914.
• [56]Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008, 10(5):593-601.